Thimazol

Thiamazole

Method of action: Antithyroid, Endocrine Therapy, Thyroid Therapy

Treatment option: Hyperthyroidism, Goiter, Thyroidectomy, Thyrotoxicosis, Surgery

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thimazol

Quick Facts

Property	Description
Active ingredient	Thiamazole (Methimazole)
Form	Oral tablet
Pharmacological class	Antithyroid agent (Thioamide derivative)
Common purpose	To reduce excessive thyroid hormone production
Origin	Synthetic compound

What Type of Medicine is Thimazol (Thiamazole)?

Thimazol is a synthetic, prescription-only therapeutic agent designed to manage an overactive thyroid gland. It is formally classified by health authorities as an antithyroid agent, specifically belonging to the chemical family known as thioamide derivatives. Its function is primarily thyrostatic, meaning it controls the condition by limiting the production of thyroid hormones. The active substance is Thiamazole, which is also recognized by its synonymous generic name, Methimazole, and acts systemically throughout the body following administration. Clinical practice guidelines frequently recognize Thiamazole as a preferred primary agent in the medical management of hyperthyroidism across various patient groups.

Composition and Form: The Thiamazole Tablet

The primary active ingredient in this medication is Thiamazole, a single, synthetic chemical compound represented by the formula C4H6N2S. Thimazol is consistently prepared for patients as an oral preparation, most commonly a tablet. This oral route of administration is utilized to ensure the active compound is absorbed systemically to reach the thyroid gland effectively. As a single-active-ingredient product, its composition focuses entirely on the specific therapeutic action of the thiamazole compound, relying on necessary solid excipients to form the final tablet structure. The drug's well-established efficacy means that it maintains its therapeutic integrity even when produced by various manufacturers under different brand names, all containing the core Thiamazole INN.

What is Thimazol's General Purpose?

The general purpose of Thimazol is to normalize thyroid function by reducing excessive hormone activity within the body. It achieves this by acting as a thyrostatic agent to control the output of the gland. The medicine's high-level function involves the inhibition of thyroid hormone synthesis. Thiamazole does this by blocking a crucial enzyme, Thyroid Peroxidase (TPO), which is required for the thyroid gland to produce the hormones Thyroxine (T4) and Triiodothyronine (T3). By limiting this production at the source, the medication gradually helps to restore metabolic equilibrium throughout the body, providing a foundation for managing the physiological state of an overactive thyroid.

Regulatory References

What side effects are possible with Thimazol?

Possible Side Effects and Safety Information: Thimazol

The safety profile of Thiamazole is officially documented across several System-Organ Classes, defining the range and severity of possible adverse reactions. These effects are generally classified by frequency, including those considered minor and those designated as serious.

Documented Adverse Reaction Categories

Adverse reactions involving the Blood and Lymphatic System, such as Agranulocytosis and Leukopenia, are of primary concern and are officially highlighted as major risks. Effects on the Hepatobiliary System (e.g., Hepatitis, Acute Liver Failure) are also documented. Minor adverse reactions are frequently reported in the Dermatological system (e.g., skin rash, pruritus), the Gastrointestinal System (e.g., nausea), and the Musculoskeletal System (e.g., arthralgia). Severe, yet rare, reactions include conditions such as ANCA-positive Vasculitis and Stevens-Johnson syndrome.

Timing and Population-Specific Safety Notes

Many of the minor, more frequently occurring adverse reactions typically manifest within the first eight weeks of treatment initiation. Conversely, the onset of severe reactions like agranulocytosis is often reported within the first 90 days of therapy.

Population-specific safety considerations are formally stated in regulatory documents. Thiamazole readily crosses the placental barrier and is associated with a risk of fetal harm, including congenital malformations, particularly with first-trimester exposure. Furthermore, the medication is contraindicated in individuals with severe hepatic insufficiency or pre-existing serious haematological conditions.

Overdose and Emergency Response

Overdose Manifestations and Outcomes

Overdosage of Thimazol (Thiamazole) is officially documented in regulatory labeling to present with several clinical manifestations. Symptoms listed include gastrointestinal effects such as nausea, vomiting, and epigastric distress, as well as systemic signs like headache, fever, swelling (edema), joint pain, and itching. Less frequent effects on the nervous system, including Central Nervous System (CNS) stimulation or depression, and skin, such as exfoliative dermatitis, are also noted.

The most severe and potentially life-threatening outcomes cited in the official profile are hematologic in nature: agranulocytosis and aplastic anemia (pancytopenia). These conditions may become apparent hours to days after the exposure event. Regulatory documents note that the risk of agranulocytosis is generally associated with daily doses of 40 mg or more in patients over 40 years of age. Furthermore, no information is available on the median lethal dose.

When to Seek Emergency Help

Regulatory guidance mandates that individuals seek immediate medical attention for suspected overdosage. Emergency services must be contacted immediately if severe, acute signs occur, such as collapse, seizure, difficulty breathing, or the inability to be awakened.

Management of overdosage involves initiating appropriate supportive treatment dictated by the patient’s clinical status. This approach is necessary because no specific antidote is known for Thiamazole overexposure. The supportive management required considers the possibility of multiple drug overdoses and drug interactions.

Therapeutic Uses of Thimazol

What Thimazol Treats: Main Uses and Benefits

Thiamazole is primarily used for the treatment of conditions characterized by periods of heightened physiological activity due to an overactive thyroid. It is relevant in conditions presenting with a systemic state of thyrotoxicosis, including Graves' disease and toxic multinodular goiter. The key therapeutic benefit supports the patient during difficult episodes by contributing to easing the overall symptom load associated with hormone excess.

The medication is relevant for easing symptom clusters that may become intense or disruptive, including rapid or irregular heartbeats (palpitations), physical signs like tremors, excessive nervousness, and persistent anxiety. It also assists in managing symptoms related to systemic imbalance, such as unexplained weight loss, profuse sweating, and severe heat intolerance. It is applied in clinical settings that involve acute or unstable symptom patterns, often used when supportive relief is needed or in scenarios requiring assistance before other therapeutic approaches.

Quick Fact: Relief for Hypermetabolic Symptoms

Thimazol supports patients during episodes of heightened discomfort by addressing cardiovascular, neurological, and metabolic symptoms, assisting with managing symptoms that interfere with daily comfort.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Thimazol (Methimazole) is governed by official regulatory criteria, including absolute prohibitions and conditional restrictions based on health status and age. The medicine is primarily approved for adults and is used for pediatric hyperthyroidism, though some jurisdictions note insufficient data for children.

Absolute Non-Eligibility

Status	Official Constraint
Contraindicated	Patients with known hypersensitivity to Thiamazole or any product component.
Contraindicated	Nursing Mothers, as the drug is known to be excreted into breast milk.
Non-Eligible for Continuation	Patients who develop agranulocytosis, aplastic anemia, or severe liver abnormality (e.g., transaminases >3 imes ULN) must discontinue the medication.

Conditional Eligibility

Population	Restriction Status
Pregnancy (First Trimester)	Restricted/Not Recommended due to potential risk of fetal malformations.
Pregnancy (Later Trimesters)	Conditional Use only, requiring the lowest possible dose.
Hepatic Impairment	Use with caution; requires prompt discontinuation if hepatic dysfunction is evident.

The official labeling explicitly limits use based on a patient's concurrent medical status and physiological state, defining when the drug is strictly prohibited or when therapy must be terminated to prevent serious harm.

What should I know about interactions with other medicines?

Thimazol Interactions with other medicines and products

Official regulatory documents define the interaction profile of Thimazol (Methimazole) primarily through changes in co-administered drug exposure, additive risks, and specific pharmacodynamic restrictions.

Clinically Significant Interactions

Classification	Interacting Agents	Official Regulatory Statement
Exposure Modification	Oral Anticoagulants (e.g., Warfarin)	Activity may be increased due to potential inhibition of vitamin K activity; additional monitoring of PT/INR is required.
Exposure Modification	Digitalis Glycosides, Beta-Blockers, Theophylline	Clearance may decrease as the patient transitions from a hyperthyroid to a euthyroid state, necessitating clinical awareness for potential adjustments.
Additive Risk	Drugs Known to Cause Agranulocytosis	Requires particular care during co-administration due to an increased, additive risk of developing this severe adverse event.

Mandatory Restrictions and Pharmacodynamic Constraints

Thimazol is contraindicated for co-administration with Sodium Iodide I-131 (Radioactive Iodine) due to the risk of reducing the efficacy of the radioactive treatment. Consequently, Thimazol must be discontinued days prior to the administration of radioactive iodine therapy. Separately, the therapeutic response to Thimazol may be attenuated by an excessive intake of iodine, whether from diet or other iodinated substances.

Mechanism of Action

Blocking New Thyroid Hormone Synthesis

The primary mechanism of Thimazol is the inhibition of the enzyme Thyroid Peroxidase (TPO) within the thyroid follicular cells. TPO catalyzes the essential steps of iodination and coupling of tyrosyl residues on thyroglobulin, which are required for the de novo biosynthesis of thyroxine (T4) and triiodothyronine (T3). By blocking TPO activity, the drug interrupts the molecular cascade, resulting in a progressive reduction of thyroid hormone synthesis and output.

Modulating Systemic Hormone Levels

Because Thimazol only inhibits the creation of new hormone, its full physiological consequence is contingent upon the natural turnover and clearance of existing circulating and stored T4 and T3. This delay in the systemic effect reflects the time required to deplete the pre-existing hormone pool. The continued synthesis inhibition modulates excessive pathway activity within metabolic signaling systems by progressively reducing the availability of systemic hormonal mediators.

Ancillary Cellular Pathway Modulation

Secondary effects include the modulation of other cellular pathways, such as potential immunomodulatory and antioxidant actions within the thyroid tissue. This ancillary activity alters specific downstream effects of cellular stress pathways, contributing to the overall physiological adjustment of the thyroid system.

Dosage and Administration Information

How Thimazol is Used: Official Administration Guidelines

Thimazol (Thiamazole/Methimazole) is an antithyroid agent administered exclusively via the oral route as tablets, available in 5 mg and 10 mg strengths. The official usage pattern follows a two-stage approach: an initial higher dose for control, followed by a reduced maintenance dose.

Dosing Schedule and Frequency

Treatment Phase	Adult Dosing Regimen	Administration Frequency
Initial Therapy	15 mg to 60 mg daily, based on the severity of the condition.	Total daily dose is typically administered in three equally divided doses at approximately 8-hour intervals.
Maintenance Therapy	5 mg to 15 mg daily.	Usually consolidated to a single daily dose after thyroid function stabilizes.

Procedural and Duration Context

For administration, the oral tablets are swallowed whole with liquid and may be taken after meals. During the initial phase, the required three-times-daily schedule is crucial for maintaining a constant amount of the medicine in the blood. If a dose is missed, it should be taken as soon as possible, but if it is near the time for the next dose, the missed dose should be skipped without doubling the dose.

The overall course duration is defined as a long-term plan, typically continuing for 6 months to 2 years to achieve disease remission. The medicine is also used for short-term periods, such as preparation before definitive procedures like thyroid surgery. For pediatric patients, the starting dose is based on body weight, using a formula of 0.4 mg/kg daily, divided into three doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Thimazol

The following summary describes the structure of the clinical research for Thimazol (Thiamazole), outlining the types of studies that have been conducted and what they monitored, without offering any clinical advice or making statements about how the medicine works for an individual.

Evidence for use in Hyperthyroidism

The core research base for examining general hyperthyroidism is composed of high-level Systematic Reviews and Meta-analyses that consolidate findings from numerous individual investigations. These reviews examine data from Randomized Controlled Trials (RCTs) and large Observational Studies. Researchers used these studies to monitor physiological changes in adults and various pediatric patient groups.

The studies were primarily designed to measure shifts in blood biomarkers, such as key thyroid hormone levels (T3 and T4), and track outcomes related to systemic or functional imbalance, including common physical symptoms associated with hormone excess. Findings indicate patterns related to the time-to-stabilization of hormone levels. Observational cohorts have also contributed to understanding how patients reported their experience and how symptoms evolved in the observed populations during the study period.

Evidence for use in Graves' Disease

The evidence for Graves' disease includes Randomized Controlled Trials that explore outcomes over a defined study interval for the condition. Research has examined measurements of the time required for hormone levels to shift to within a monitored range and monitored changes in physical signs, such as the size of the thyroid gland. Studies also monitored the frequency of a condition return (relapse) following the end of the defined study interval.

Long-term Studies and Follow-up Data

Studies of Thimazol have been conducted across both short-term stabilization periods and extended follow-up durations. The research describes the physiological status of patients followed for several years, monitoring outcomes related to systemic imbalance. These findings indicate patterns related to the sustained stability of the thyroid.

However, long-term effects are not fully established in all contexts. Research is ongoing, and there is limited information for long-term outcomes, particularly concerning the precise rate and timing of a condition return (relapse) across diverse patient groups following the cessation of therapy.

What Remains Uncertain in the Research

The overall evidence landscape for Thimazol, while extensive, is not without its research gaps. Comparative evidence is lacking for certain definitive treatments across all relevant subgroups, making it difficult to draw broad conclusions about the comparative evidence.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Thimazol (FAQ)

Q: Can I stop taking Thimazol if my symptoms improve?

The regulatory information indicates that abruptly stopping treatment with Thimazol is generally not recommended, even when symptoms appear to improve. Stopping suddenly may be associated with withdrawal symptoms or a return of original symptoms.

A healthcare provider should be consulted before making any changes. They can advise on a gradual reduction plan, which is typically the recommended method for discontinuing treatment.

Q: What is the best time of day to take Thimazol?

Official prescribing information commonly suggests taking Thimazol in the morning. Taking this type of medication later in the day has been associated with potential sleep disruption in some individuals.

Specific instructions for a missed dose should be obtained directly from the prescribing healthcare provider or pharmacist, as advice can vary based on the individual's prescribed regimen.

Q: Does Thimazol cure depression?

Thimazol is used to manage and may help reduce the symptoms of depression, but it is not considered a cure for the condition itself. Like other medications in its class, it is thought to influence certain chemical messengers in the brain.

It is important to understand that medication is one part of a comprehensive treatment plan. Consulting with a healthcare provider regarding the appropriate duration of treatment is essential for managing long-term benefits.

How should Thimazol be stored and disposed of?

How to Store and Dispose of Thimazol (Methimazole)

Official regulatory documents define specific conditions for storing and disposing of Thimazol tablets to maintain product stability and safety.

Storage Requirements

Detail	Official Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Protection	Keep the container tightly closed to protect the tablets from moisture. Store in the original container.
Child Safety	Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired Thimazol should be disposed of via an authorized drug take-back program. If a program is unavailable, mix the uncrushed tablets with an undesirable substance (like dirt or cat litter) in a sealed bag before placing in the household trash. Do not flush this medication down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Taiwan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z